Prescription medicine
Ethinyl estradiol and ferrous bisglycinate and levonorgestrel Brand names: Minzoya
Ethinyl estradiol and ferrous bisglycinate and levonorgestrel (Minzoya) is a prescription medicine. FDA's NDC Directory lists it from 1 generic labeler, and pharmacies paid $3.45 per minzoya-28 tablet in the October 7, 2026 NADAC survey.
- Generic listed
- Boxed warning
Check it at the source: the ethinyl estradiol and ferrous bisglycinate and levonorgestrel FDA label on DailyMed (effective January 9, 2025, Lupin Pharmaceuticals, Inc.); every ethinyl estradiol and ferrous bisglycinate and levonorgestrel label on DailyMed.
Highlights of the record
FDA label of January 9, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke [see Contraindications ( 4 )]. WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full Prescribing Information for complete Boxed Warning Minzoya is contraindicated in women over 35 years old who smoke. ( 4 ) Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use.
Used for
From the label: indications and usageMinzoya™ is indicated for use by females of reproductive potential to prevent pregnancy.
Forms and strengths
Kit.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 1 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $3.45 per tablet Minzoya-28 tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
What is ethinyl estradiol and ferrous bisglycinate and levonorgestrel used for?
From the label: indications and usageMinzoya™ is indicated for use by females of reproductive potential to prevent pregnancy. Minzoya is a progestin/estrogen COC indicated for use by females of reproductive potential to prevent pregnancy.
Conditions named in the indications of ethinyl estradiol and ferrous bisglycinate and levonorgestrel's FDA labels, with every medicine labeled for each:
Source: FDA drug label (MINZOYA), Lupin Pharmaceuticals, Inc., effective January 9, 2025 (SPL set d5ebd7fa-c388-4619-8dcb-e862e4ce5285), via openFDA; the full label on DailyMed
What does the patient leaflet for ethinyl estradiol and ferrous bisglycinate and levonorgestrel say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about Minzoya?Do not use Minzoya if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke.
From the patient leaflet: How should I store Minzoya?Store Minzoya at room temperature between 68°F to 77°F (20°C to 25°C). • Keep Minzoya and all medicines out of the reach of children. • Store away from light.
Source: FDA drug label (MINZOYA), Lupin Pharmaceuticals, Inc., effective January 9, 2025 (SPL set d5ebd7fa-c388-4619-8dcb-e862e4ce5285), via openFDA; the full label on DailyMed
Is there a generic for ethinyl estradiol and ferrous bisglycinate and levonorgestrel (Minzoya)?
No generic ethinyl estradiol and ferrous bisglycinate and levonorgestrel is approved (Drugs@FDA, October 8, 2026).
FDA's NDC Directory lists ethinyl estradiol and ferrous bisglycinate and levonorgestrel from 1 labeler under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for ethinyl estradiol and ferrous bisglycinate and levonorgestrel (Minzoya)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $3.45 per Minzoya-28 tablet, down 31% from $5.00 on October 8, 2025. The survey records the price, not the reason for a change; large moves often follow a new generic or a list-price change. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Minzoya-28 tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Minzoya-28 tablet | Generic | $3.45 per tablet | $103.36 | -31% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the ethinyl estradiol and ferrous bisglycinate and levonorgestrel label say about other medicines?
The ethinyl estradiol and ferrous bisglycinate and levonorgestrel label names 35 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Acetaminophen | drug interactions | Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. |
| Aprepitant | drug interactions | Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. |
| Ascorbic acid | drug interactions | Ascorbic acid and acetaminophen may increase plasma EE concentrations, possibly by inhibition of conjugation. |
| Atazanavir | drug interactions | … lopinavir/ritonavir, tipranavir/ritonavir, boceprevir, telaprevir, nevirapine and efavirenz] or increase [e.g., indinavir, atazanavir/ritonavir and etravirine]). |
| Atorvastatin | drug interactions | Substances Increasing the Plasma Concentrations of COCs Co-administration of atorvastatin or rosuvastatin and certain COCs containing EE increase AUC values for EE by approximately 20 to 25%. |
| Bosentan | drug interactions | Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. |
| Carbamazepine | drug interactions | Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. |
| Colesevelam | drug interactions | Colesevelam, a bile acid sequestrant, given together with a COC, has been shown to significantly decrease the AUC of ethinyl estradiol (EE). |
| Cyclosporine | drug interactions | Contraceptives on Other Drugs Combined oral contraceptives containing EE may inhibit the metabolism of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. |
| Darunavir | drug interactions | … protease inhibitors and non- nucleoside reverse transcriptase inhibitors (decrease [e.g., nelfinavir, ritonavir, darunavir/ritonavir, (fos) amprenavir/ritonavir, lopinavir/ritonavir, tipranavir/ritonavir, boceprevir, telaprevir, nevirapine and efavirenz] or increase [e.g., indinavir, atazanavir/ritonavir and … |
| Efavirenz | drug interactions | … (fos) amprenavir/ritonavir, lopinavir/ritonavir, tipranavir/ritonavir, boceprevir, telaprevir, nevirapine and efavirenz] or increase [e.g., indinavir, atazanavir/ritonavir and etravirine]). |
| Etravirine | drug interactions | … tipranavir/ritonavir, boceprevir, telaprevir, nevirapine and efavirenz] or increase [e.g., indinavir, atazanavir/ritonavir and etravirine]). |
| Felbamate | drug interactions | Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. |
| Fluconazole | drug interactions | CYP3A4 inhibitors, such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma hormone concentrations. |
Every other medicine the ethinyl estradiol and ferrous bisglycinate and levonorgestrel label names
| Medicine named | Section | What the label says |
|---|---|---|
| Griseofulvin | drug interactions | … include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. |
| Itraconazole | drug interactions | CYP3A4 inhibitors, such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma hormone concentrations. |
| Ketoconazole | drug interactions | CYP3A4 inhibitors, such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma hormone concentrations. |
| Lamotrigine | drug interactions | Combined oral contraceptives have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine. |
| Lopinavir and ritonavir | drug interactions | Human Immunodeficiency Virus (HIV)/ Hepatitis C Virus (HCV) Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors Significant changes (increase or decrease) in the plasma … |
| Morphine | drug interactions | Combined oral contraceptives have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine. |
| Nelfinavir | drug interactions | … non- nucleoside reverse transcriptase inhibitors (decrease [e.g., nelfinavir, ritonavir, darunavir/ritonavir, (fos) amprenavir/ritonavir, lopinavir/ritonavir, tipranavir/ritonavir, boceprevir … |
| Nevirapine | drug interactions | … lopinavir/ritonavir, tipranavir/ritonavir, boceprevir, telaprevir, nevirapine and efavirenz] or increase [e.g., indinavir, atazanavir/ritonavir and etravirine]). |
| Oxcarbazepine | drug interactions | … phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. |
| Phenytoin | drug interactions | Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine … |
| Prednisolone | drug interactions | Contraceptives on Other Drugs Combined oral contraceptives containing EE may inhibit the metabolism of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) … |
| Rifabutin | drug interactions | … bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. |
| Ritonavir | contraindications | Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations [see Warnings and Precautions ( 5.3 )]. |
| Rosuvastatin | drug interactions | Substances Increasing the Plasma Concentrations of COCs Co-administration of atorvastatin or rosuvastatin and certain COCs containing EE increase AUC values for EE by approximately 20 to 25%. |
| Rufinamide | drug interactions | … felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. |
| Salicylic acid | drug interactions | Combined oral contraceptives have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine. |
| Temazepam | drug interactions | Combined oral contraceptives have been shown to decrease plasma concentrations of acetaminophen, clofibric acid, morphine, salicylic acid, temazepam and lamotrigine. |
| Theophylline | drug interactions | … the metabolism of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. |
| Tizanidine | drug interactions | … of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. |
| Topiramate | drug interactions | … carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. John's wort. |
| Voriconazole | drug interactions | CYP3A4 inhibitors, such as itraconazole, voriconazole, fluconazole, grapefruit juice, or ketoconazole may increase plasma hormone concentrations. |
Check ethinyl estradiol and ferrous bisglycinate and levonorgestrel against other medicines
Source: FDA drug label (MINZOYA), Lupin Pharmaceuticals, Inc., effective January 9, 2025 (SPL set d5ebd7fa-c388-4619-8dcb-e862e4ce5285), via openFDA; the full label on DailyMed
What next?
- Check an interaction
- what two or more labels say about each other